Compare · CELC vs CNC
CELC vs CNC
Side-by-side comparison of Celcuity Inc. (CELC) and Centene Corporation (CNC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELC and CNC operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $32.11B, about 7.1x CELC ($4.51B).
- CNC has been more active in the news (12 items in the past 4 weeks vs 8 for CELC).
- CNC has more recent analyst coverage (25 ratings vs 14 for CELC).
- Company
- Celcuity Inc.
- Centene Corporation
- Price
- -
- -
- Market cap
- $4.51B
- $32.11B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 8
- 12
- Recent ratings
- 14
- 25
Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest CELC
- Chief Science Officer Laing Lance G. was granted 20,000 shares, increasing direct ownership by 2% to 1,271,000 units (SEC Form 4)
- Chief Executive Officer Sullivan Brian F. was granted 80,000 shares, increasing direct ownership by 6% to 1,450,199 units (SEC Form 4)
- Chief Financial Officer Hahne Vicky was granted 16,000 shares, increasing direct ownership by 73% to 37,808 units (SEC Form 4)
- SEC Form 10-Q filed by Celcuity Inc.
- Celcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13G filed by Celcuity Inc.
- Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
- Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
- SEC Form SCHEDULE 13G filed by Celcuity Inc.
Latest CNC
- California Community Health Workers and Doulas Can Spend More Time Helping Medi-Cal Members, Thanks to Health Net's $900,000 Grant to Pear Suite
- Coordinated Care Brings Free Health Screenings to Washington Communities with Statewide Vision & Dental Van Tour
- Superior HealthPlan has supported more than 312,000 Texas pregnancies since 2022 through the Start Smart for Your Baby® program
- Secretary & General Counsel Koster Christopher sold $3,111,332 worth of shares (47,603 units at $65.36), decreasing direct ownership by 13% to 305,354 units (SEC Form 4)
- Centene Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Centene Announces Planned Chief Financial Officer Transition
- Sixty Compton, California Students to be Selected for Leadership and Health Advocacy Training, Powered by Health Net's $412,000 Investment
- Carolina Complete Health Supports Young Leaders Through AMEXCAN Summer Camp
- MHS Serves Announces Recipients of over $2 Million Investment in Hoosier Employment
- Health Net Providing Special Assistance to Members and Providers Affected by Gann Fire in Calaveras County